Get­ting to work on pipeline con­struc­tion, new Ipsen CEO forges $1B deal to buy Mer­ri­mack’s strug­gling Onivyde

Mer­ri­mack Phar­ma­ceu­ti­cals and Ipsen, two biotechs look­ing to re­or­ga­nize and move up in the world, have struck a bil­lion-dol­lar deal for a floun­der­ing can­cer ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER